Brokers Issue Forecasts for VolitionRx Limited’s FY2022 Earnings (NYSEAMERICAN:VNRX)

VolitionRx Limited (NYSEAMERICAN:VNRXGet Rating) – Equities research analysts at Zacks Investment Research issued their FY2022 earnings per share (EPS) estimates for VolitionRx in a note issued to investors on Monday, April 11th. Zacks Investment Research analyst S. Ralston anticipates that the medical research company will post earnings of ($0.40) per share for the year.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of VolitionRx in a research note on Friday, February 18th.

Shares of NYSEAMERICAN VNRX opened at $2.95 on Wednesday. VolitionRx has a twelve month low of $2.38 and a twelve month high of $4.14. The firm has a market cap of $158.64 million, a P/E ratio of -6.41 and a beta of 1.73. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 0.12.

VolitionRx (NYSEAMERICAN:VNRXGet Rating) last announced its earnings results on Wednesday, March 30th. The medical research company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). VolitionRx had a negative return on equity of 100.42% and a negative net margin of 28,471.43%.

In other VolitionRx news, insider Jason Bradley Md Terrell sold 10,000 shares of VolitionRx stock in a transaction on Monday, April 11th. The shares were sold at an average price of $2.75, for a total value of $27,500.00. Following the completion of the sale, the insider now directly owns 27,249 shares of the company’s stock, valued at $74,934.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 15.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Lagoda Investment Management L.P. grew its holdings in shares of VolitionRx by 7.9% during the fourth quarter. Lagoda Investment Management L.P. now owns 3,283,913 shares of the medical research company’s stock valued at $10,311,000 after buying an additional 240,569 shares during the last quarter. Morgan Stanley grew its holdings in shares of VolitionRx by 2.9% during the second quarter. Morgan Stanley now owns 609,173 shares of the medical research company’s stock valued at $2,005,000 after buying an additional 17,092 shares during the last quarter. BlackRock Inc. grew its holdings in shares of VolitionRx by 0.9% during the fourth quarter. BlackRock Inc. now owns 542,218 shares of the medical research company’s stock valued at $1,703,000 after buying an additional 4,867 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of VolitionRx by 3.3% during the third quarter. Geode Capital Management LLC now owns 270,820 shares of the medical research company’s stock valued at $839,000 after buying an additional 8,718 shares during the last quarter. Finally, Cowen Prime Advisors LLC grew its holdings in shares of VolitionRx by 5.1% during the third quarter. Cowen Prime Advisors LLC now owns 62,200 shares of the medical research company’s stock valued at $193,000 after buying an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 11.49% of the company’s stock.

VolitionRx Company Profile (Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers.

Recommended Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.